Human medicinehttps://www.ema.europa.eu/en/homepageHuman medicineen-gbCopyright: (C) European Medicines AgencyWed, 17 Jul 2024 06:51:50 +0200Fri, 28 Jun 2024 12:00:25 +0200Summary of opinion: Betmiga, 27/06/2024 Positivehttps://www.ema.europa.eu/en/medicines/human/variation/betmigaSummary of opinion: Betmiga, 27/06/2024 Positivehttps://www.ema.europa.eu/en/medicines/human/variation/betmigaFri, 28 Jun 2024 12:00:25 +0200Human medicineHuman medicines European public assessment report (EPAR): Betmiga, mirabegron, Date of authorisation: 20/12/2012, Revision: 15, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/betmigaHuman medicines European public assessment report (EPAR): Betmiga, mirabegron, Date of authorisation: 20/12/2012, Revision: 15, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/betmigaTue, 28 May 2024 11:30:00 +0200Human medicineOpinion/decision on a Paediatric investigation plan (PIP): Betmiga, Mirabegron, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Uro-nephrology, PIP number: P/0550/2022https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000597-pip02-10-m09Opinion/decision on a Paediatric investigation plan (PIP): Betmiga, Mirabegron, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Uro-nephrology, PIP number: P/0550/2022https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000597-pip02-10-m09Wed, 14 Feb 2024 17:13:00 +0100Human medicineBetmiga : EPAR - All Authorised presentationshttps://www.ema.europa.eu/system/files/documents/all-authorised-presentations/ema-other-h-2388-aa_en.pdfBetmiga : EPAR - All Authorised presentationshttps://www.ema.europa.eu/system/files/documents/all-authorised-presentations/ema-other-h-2388-aa_en.pdfFri, 05 Nov 2021 01:00:00 +0100Human medicine